Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Portal Hypertension
Interventions: TIPS with 3D Overlay; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Alzheimer's Disease
Interventions: Telmisartan 20mg, Telmisartan 40mg, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Telmisartan 80, Amlodipine 10; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 15
States / cities: Long Beach, California • Tustin, California • Fort Lauderdale, Florida + 12 more

Conditions: Blood Pressure, Endothelial Dysfunction, Hypertension
Interventions: Inspiratory muscle strength training, Brisk walking; Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 50 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Hypertension
Interventions: olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan; Drug
Lead sponsor: The Louis & Rachel Rudin Foundation; Other
Eligibility: 40 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: The Bronx, New York

Conditions: Hypertension, Bipolar Disorder
Interventions: iTAB-CV; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 21 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glaucoma, Retinal Disease, Corneal Disease
Interventions: Not listed
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Interventions: Frespaciguat, Placebo to Frespaciguat; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 22 more

Conditions: Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions: Milrinone, Placebo (5% Dextrose); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 0 Hours to 168 Hours
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more

Conditions: GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma
Interventions: Ripcord removal; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions: Oral Ifetroban, Oral Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more

Conditions: Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
Interventions: Collaborative Model of Primary care and Subspecialty care; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 18,268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Farmington, Connecticut • Arlington, Texas • Dallas, Texas

Conditions: Hypertension (HTN), Hypertension
Interventions: Arugula Extract, Psyllium Husk; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Metabolic Syndrome
Interventions: ELM Group, ELM Classes, ELM Individual; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Systolic, Stiffness, Aortic
Interventions: Clonidine, Hydrochlorothiazide, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension
Interventions: A structured, telephone-based educational outreach to encourage HBPM; Other
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pulmonary Hypertension
Interventions: Inhaled Iloprost; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Up to 7 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 28
States / cities: Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 23 more

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Netarsudil ophthalmic solution 0.02%, Artificial tears; Drug
Lead sponsor: East Coast Institute for Research; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypertension
Interventions: blood pressure; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Uncontrolled Hypertension, Atrial Fibrillation
Interventions: Boston Scientific Vessix Renal Denervation System; Device
Lead sponsor: Vivek Reddy; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 6
States / cities: Sacramento, California • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Pulmonary Arterial Hypertension
Interventions: sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 11
States / cities: Atlanta, Georgia • Grand Rapids, Michigan • Wooster, Ohio + 2 more

Conditions: Preeclampsia, Hypertensive Disorder of Pregnancy, Hypertension, Gestational Hypertension, Gestational Hypertension After Childbirth
Interventions: Enalapril, Standard treatment; Drug · Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure

Health Evaluation in African Americans Using RAS Therapy

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

Novel Time-efficient Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure

Renin Profiling in Selection of Initial Antihypertensive Drug

Medication Adherence in Hypertensive Individuals With Bipolar Disorder

Nidek RS3000 Comparative Study

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Milrinone in Congenital Diaphragmatic Hernia

Effect of Late Ripcord Removal From Glaucoma Drainage Device

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Improving Chronic Disease Management With Pieces

Under Pressure: Arugula Extract's Effect on Blood Pressure in Hypertensive Individuals

A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)

Sympathetic Regulation of Large Artery Stiffness in Humans With ISH

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Increasing the Use of Self Measured Home Blood Pressure Logs in the Management of Hypertension

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Take the Pressure Off, NYC!

Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation

Effects of Oral Sildenafil on Mortality in Adults With PAH

Cardiovascular Protection After Preeclampsia With Enalapril